RPG Life Sciences enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
4,703————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
27323415511024.8
179————
20.020.0———
4,630————
−253−214———
₹2,799.52————
886625———
2.3%3.2%———
0.00×————
6.06×————
29.62×————
34.95×————
Reference items — trailing FY values
764708———
156147———
132126———
—56.577.994.490.8
−8.9−8.977.994.490.8
—−9.1———
—65.4———
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health
₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,703 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————4,703.3
- Cash, Equiv & ST Investments24.8109.9154.6234.4272.8
+ Minority Interest————179.3
+ Total Debt———20.020.0
Enterprise Value————4,629.7
Net Debt (memo)———-214.4-252.8
EV per Share————2,799.52
Total Capital———625.4886.5
Total Debt/Total Capital———3.202.26
Total Debt/EV————0.00
EV/Sales————6.06
EV/EBITDA————29.62
EV/EBIT————34.95
Reference Items — Trailing FY Values
Sales———707.5764.3
EBITDA———147.1156.3
EBIT———125.6132.5
Operating Cash Flow90.894.477.956.5—
Free Cash Flow90.894.477.9-8.9-8.9
FCFF (free cash flow to the firm)———-9.1—
Capital Expenditure———65.4—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.